Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and early evaluation of strong candidate biomarkers and biomarker signatures for neurological and neuromuscular disorders. The focus is on identifying and initially biologically, analytically, and clinically evaluating biomarkers and biomarker signatures. Although animal studies can be included, the research must also include preliminary human evaluation using standardized human samples or datasets. The goal is to deliver candidate biomarkers or biomarker signatures ready for definitive analytical and clinical validation studies. Key aspects of this opportunity include: • The development of biomarkers or composite biomarkers for neurological and neuromuscular disorders • The inclusion of preliminary human evaluation using carefully standardized human samples or datasets • The goal of delivering candidate biomarkers or biomarker signatures ready for definitive analytical and clinical validation studies • The opportunity is open to various applicant types, including public and state-controlled institutions of higher education, non-profits, and small businesses • The funding instrument for this opportunity is a grant